Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för pavinetant. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2018-08-01

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action.

Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Mohideen P, Lin VH, Stern TP, Panay N, Hunter MS, Webber LC, Dhillo WS.

Menopause · research support, non-u.s. gov't; research-article; journal article · DOI 10.1097/gme.0000000000001090

Bibliografisk träff 2018-01-01

Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women.

Skorupskaite K, George JT, Veldhuis JD, Anderson RA.

J Clin Endocrinol Metab · research support, non-u.s. gov't; research-article; journal article · DOI 10.1210/jc.2017-01306

Bibliografisk träff 2017-09-05

Neurokinin 3 receptor antagonism decreases gonadotropin and testosterone secretion in healthy men.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA.

Clin Endocrinol (Oxf) · journal article · DOI 10.1111/cen.13445

Bibliografisk träff 2017-04-05

Neurokinin 3 Receptor Antagonism Reveals Roles for Neurokinin B in the Regulation of Gonadotropin Secretion and Hot Flashes in Postmenopausal Women.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA.

Neuroendocrinology · research support, non-u.s. gov't; journal article · DOI 10.1159/000473893

Bibliografisk träff 2017-04-03

Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, Doyle C, Papadopoulou DA, Bloom SR, Mohideen P, Panay N, Hunter MS, Veldhuis JD, Webber LC, Huson L, Dhillo WS.

Lancet · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(17)30823-1

Bibliografisk träff 2016-09-16

Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA.

J Clin Endocrinol Metab · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1210/jc.2016-2132

Bibliografisk träff 2016-07-26

Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial.

George JT, Kakkar R, Marshall J, Scott ML, Finkelman RD, Ho TW, Veldhuis J, Skorupskaite K, Anderson RA, McIntosh S, Webber L.

J Clin Endocrinol Metab · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1210/jc.2016-1202

Bibliografisk träff 2016-01-18

Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.

Xu H, Li J, Webber L, Kakkar R, Chen Y, Al-Huniti N.

J Clin Pharmacol · clinical trial, phase ii; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/jcph.680

Bibliografisk träff 2015-02-01

Role of a neurokinin B receptor antagonist in the regulation of ovarian function in healthy women.

Skorupskaite K, George J, Anderson RA.

Lancet · journal article · DOI 10.1016/s0140-6736(15)60407-x

Bibliografisk träff 2014-04-01

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ.

J Clin Psychopharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1097/jcp.0000000000000071

Bibliografisk träff 2010-11-01

In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW.

Xenobiotica · journal article · DOI 10.3109/00498254.2010.512670